HSE begins talks on CF drug Orkambi

News relief to patients with cystic fibrosis and families

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
28th August, 2016
Cystic fibrosis drug Orkambi

Negotiations between the state and the manufacturer of cystic fibrosis drug Orkambi have finally begun.

The news will be a relief to patients with cystic fibrosis and their families, who had begun to question why the health service had yet to decide whether it would seek to provide the drug – at a cost of €160,000 per patient per year.

The National Centre for Pharmacoeconomics (NCPE) recommended against funding the drug in June, but that...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Analysis: Variants and vaccines make projecting path of virus more complex

Health Rachel Lavin 2 days ago

HSE’s latest private hospitals Covid deal estimated to cost €47 million a month

Health Daniel Murray 6 days ago

Key public health posts remain vacant

Health Daniel Murray 6 days ago

Breakdown of HSE’s €1.6 billion war chest to fight Covid-19

Health Daniel Murray 6 days ago